Eltrombopag in Thrombocytopenic Chronic Lymphocytic Leukemia (CLL) Patients (CLL2S Study of GCLLSG)
Status:
Terminated
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to find the appropriate dose of eltrombopag in thrombocytopenic CLL
patients, that shortens the duration of the thrombocytopenia and achieves platelet count of ≥
100/nl prior to the start of chemotherapy containing alkylating agents and/or Purine
Analogues.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Ulm
Collaborators:
German CLL Study Group GlaxoSmithKline WiSP Wissenschaftlicher Service Pharma GmbH